당뇨병성 신증의 병태생리

키워드

참고문헌 (62)

1. Collins AJ, "Excerpts from the United States Renal Data System 2007 annual data report", Am J Kidney Dis, 51(1), pp.S1~S320 (2008)
2. Mehls O, "Report on management of renal failure in Europe, XXV, 1994: the child-adult interface. The EDTA-ERA Registry. European Dialysis and Transplant Association- European Renal Association", Nephrol Dial Transplant, 1(1), pp.22~36 (1996)
3. Fioretto P, "Patterns of renal injury in NIDDM patients with microalbuminuria", Diabetologia, 39, pp.1569~1576 (1996)
4. Fioretto P, "Histopathology of diabetic nephropathy", Semin Nephrol, 27, pp.195~207 (2007)
5. Cooper ME, "Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy", Diabetologia, 44, pp.1957~1972 (2001)
6. Ziyadeh FN, "Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy", Curr Diabetes Rev, 4, pp.39~45 (2008)
7. Wolf G, "Cellular and molecular mechanisms of proteinuria in diabetic nephropathy", Nephron Physiol, 106, pp.26~31 (2007)
8. Navar LG, "Tubular fluid concentrations and kidney contents of angiotensins I and II in anesthetized rats", J Am Soc Nephrol, 5, pp.1153~1158 (1994)
9. Yoo TH, "Activation of the renin-angiotensin system within podocytes in diabetes", Kidney Int, 71, pp.1019~1027 (2007)
10. Hostetter TH, "The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies", Am J Med, 72, pp.375~380 (1982)
11. Zatz R, "Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension", J Clin Invest, 77, pp.1925~1930 (1986)
12. Kagami S, "Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells", J Clin Invest, 93, pp.2431~2437 (1994)
13. Nagahama T, "Role of protein kinase C in angiotensin II-induced constriction of renal microvessels", Kidney Int, 57, pp.215~223 (2000)
14. Ruiz-Ortega M, "Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms", Circ Res, 86, pp.1266~1272 (2000)
15. Wolf G, "Angiotensin converting- enzyme inhibitor treatment reduces glomerular p16INK4 and p27Kip1 expression in diabetic BBdp rats", Diabetologia, 42, pp.1425~1432 (1999)
16. Xu ZG, "Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli", Kidney Int, 67, pp.944~952 (2005)
17. Bucala R, "Advanced glycosylation endproducts in diabetic renal disease: clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition", Blood Purif, 13, pp.160~170 (1995)
18. Makita Z, "Advanced glycosylation end products in patients with diabetic nephropathy", N Engl J Med, 325, pp.836~842 (1991)
19. Tanji N, "Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease", J Am Soc Nephrol, 11, pp.1656~1666 (2000)
20. Bohlender JM, "Advanced glycation end products and the kidney", Am J Physiol Renal Physiol, 289, pp.F645~F659 (2005)
21. Bierhaus A, "Understanding RAGE, the receptor for advanced glycation end products", J Mol Med, 83, pp.876~886 (2005)
22. Yamamoto Y, "Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice", J Clin Invest, 108, pp.261~268 (2001)
23. Flyvbjerg A, "Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice", Diabetes, 53, pp.166~172 (2004)
24. Greene DA, "Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications", N Engl J Med, 316, pp.599~606 (1987)
25. Kapor-Drezgic J, "Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent", J Am Soc Nephrol, 10, pp.1193~1203 (1999)
26. Tilton RG, "Province MA, Sherman WR, Kilo C, Williamson JR. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors", Diabetes, 38, pp.1258~1270 (1989)
27. McAuliffe AV, "Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion", Nephron, 80, pp.277~284 (1998)
28. Pedersen MM, "Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition", Diabetes, 40, pp.527~531 (1991)
29. Brownlee M, "Biochemistry and molecular cell biology of diabetic complications", Nature, 414, pp.813~820 (2001)
30. Nishikawa T, "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage", Nature, 404, pp.787~790 (2000)
31. Lee HB, "Reactive oxygen species- regulated signaling pathways in diabetic nephropathy", J Am Soc Nephrol, 14(8), pp.S241~S245 (2003)
32. Phillips AO, "The role of renal proximal tubular cells in diabetic nephropathy", Curr Diab Rep, 3, pp.491~496 (2003)
33. Onozato ML, "Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB", Kidney Int, 61, pp.186~194 (2002)
34. Koo JR, "Antioxidant therapy potentiates antihypertensive action of insulin in diabetic rats", Clin Exp Hypertens, 24, pp.333~344 (2002)
35. Xia P, "Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia", Diabetes, 43, pp.1122~1129 (1994)
36. Studer RK, "Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium", Diabetes, 42, pp.118~126 (1993)
37. Inoguchi T, "Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase", J Am Soc Nephrol, 14(8), pp.S227~S232 (2003)
38. Scivittaro V, "AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells", Am J Physiol Renal Physiol, 278, pp.F676~F683 (2000)
39. Haneda M, "Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions", J Diabetes Complications, 9, pp.246~248 (1995)
40. Kang SW, "MAPK and MAPK kinase 3", 6 mRNA and activities are increased in early diabetic glomeruli, 2001, pp.60, 543~552
41. Lander HM, "Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress", J Biol Chem, 272, pp.17810~17814 (1997)
42. Choi ME, "Mechanism of transforming growth factor-beta1 signaling", Kidney Int Suppl, 77, pp.S53~S58 (2000)
43. Kang SW, "Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes", J Am Soc Nephrol, 14, pp.3178~3187 (2003)
44. Jung DS, "FR167653 inhibits fibronectin expression and apoptosis in diabetic glomeruli and in high-glucose-stimulated mesangial cells", Am J Physiol Renal Physiol, 295, pp.F595~F604 (2008)
45. Pieper GM, "Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C", J Cardiovasc Pharmacol, 30, pp.528~532 (1997)
46. Yan SD, "Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors", binding proteins, 1994, pp.269, 9889~9897
47. Lee FT, "Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy", J Am Soc Nephrol, 15, pp.2139~2151 (2004)
48. Sharma K, "Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-beta as a key mediator", Diabetes, 44, pp.1139~1146 (1995)
49. Leask A, "TGF-beta signaling and the fibrotic response", FASEB J, 18, pp.816~827 (2004)
50. Schiffer M, "Smad proteins and transforming growth factor-beta signaling", Kidney Int Suppl, 77, pp.S45~S52 (2000)
51. Burt DJ, "P38 mitogen-activated protein kinase mediates hexosamine- induced TGFbeta1 mRNA expression in human mesangial cells", Diabetologia, 46, pp.531~537 (2003)
52. Dorado F, "The mitogen- activated protein kinase Erk5 mediates human mesangial cell activation", Nephrol Dial Transplant, 23, pp.3403~3411 (2008)
53. Wolf G, "Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway", Kidney Int, 70, pp.1914~1919 (2006)
54. Sharma K, "Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice", Diabetes, 45, pp.522~530 (1996)
55. Cha DR, "Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats", J Endocrinol, 183, pp.183~194 (2004)
56. Cha DR, "Role of vascular endothelial growth factor in diabetic nephropathy", Kidney Int Suppl, 77, pp.S104~S112 (2000)
57. de Vriese AS, "Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes", J Am Soc Nephrol, 12, pp.993~1000 (2001)
58. Flyvbjerg A, "Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody", Diabetes, 51, pp.3090~3094 (2002)
59. Eremina V, "Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival", J Am Soc Nephrol, 17, pp.724~735 (2006)
60. Hasegawa G, "Shibayama Y, Ienaga K, Kondo M. Possible role of tumor necrosis factor and interleukin- 1 in the development of diabetic nephropathy", Kidney Int, 40, pp.1007~1012 (1991)
61. Ruef C, "Mesangial cell-matrix interactions: effects on mesangial cell growth and cytokine secretion", Am J Pathol, 141, pp.429~439 (1992)
62. Park J, "MCP-1", CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells, 2008, pp.295, F749~F757

관련 논문AI추천